Picard Medical, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
Richard Fang became Interim CEO after Patrick departed. Company reported Q1 2026: 85% YoY revenue growth, 28% gross margin improvement, 116% U.S. revenue growth. Board seeks stockholder approval for reverse split (1:15 to 1:50 ratio) due to NYSE listing noncompliance (stockholders' equity below $4M threshold); creation of Class B stock (15M shares, 20 votes each) for financing flexibility; and ratification of MaloneBailey LLP as auditor. Emperor next-gen artificial heart platform in development with FDA Breakthrough designation submission planned by end-2026, IDE application targeted 2028, early feasibility study 2029. Fully diluted share count: 118M shares.
Why this rating
Interim CEO change + NYSE compliance risk + aggressive reverse split signal distress, but strong Q1 growth and product progress offset concerns. Material relative to $130.8M market cap.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.